electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference

ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will be presenting at the Canaccord Genuity 42nd Annual Growth Conference.

Canaccord Genuity 42nd Annual Growth Conference
Date: Thursday, August 11, 2022
Time: 8:30 AM EDT
Webcast: Canaccord Webcast

Following the conferences, a webcast replay of the presentations will be available on the Investor section of the company’s website, electroCore.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital